A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination

Journal of Immunology

Volumn 186, Issue 6, 2011, Pages 3606-3614

  Beernink, Peter T ^a   Shaughnessy, Jutamas ^b   Braga, Emily M ^a   Liu, Qin ^b   Rice, Peter A ^b   Ram, Sanjay ^b   Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; COMPLEMENT FACTOR H; MENINGOCOCCAL FACTOR H BINDING PROTEIN VACCINE; MENINGOCOCCAL GROUP C POLYSACCHARIDE PROTEIN CONJUGATE VACCINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBODY RESPONSE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BINDING, COMPETITIVE; BLOOD BACTERICIDAL ACTIVITY; COMPLEMENT FACTOR H; FEMALE; HUMANS; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEISSERIA MENINGITIDIS; VACCINES, CONJUGATE;

EID: 79953181620     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003470     Document Type: Article

References (50)

1. Serruto, D., R. Rappuoli, M. Scarselli, P. Gros, and J. A. van Strijp. 2010. Molecular mechanisms of complement evasion: learning from staphylococci and meningococci. Nat. Rev. Microbiol. 8: 393-399.
2. Meri, S., M. Jördens, and H. Jarva. 2008. Microbial complement inhibitors as vaccines. Vaccine 26(Suppl 8): I113-I117.
3. Fearon, D. T., and K. F. Austen. 1977. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc. Natl. Acad. Sci. USA 74: 1683-1687.
4. Weiler, J. M., M. R. Daha, K. F. Austen, and D. T. Fearon. 1976. Control of the amplification convertase of complement by the plasma protein beta1H. Proc. Natl. Acad. Sci. USA 73: 3268-3272.
5. Pangburn, M. K., R. D. Schreiber, and H. J. Müller-Eberhard. 1977. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J. Exp. Med. 146: 257-270.
6. Sim, R. B., T. M. Twose, D. S. Paterson, and E. Sim. 1981. The covalent-binding reaction of complement component C3. Biochem. J. 193: 115-127. (Pubitemid 11182631)
7. Whaley, K., and S. Ruddy. 1976. Modulation of the alternative complement pathways by beta 1 H globulin. J. Exp. Med. 144: 1147-1163.
8. Davila, S., V. J. Wright, C. C. Khor, K. S. Sim, A. Binder, W. B. Breunis, D. Inwald, S. Nadel, H. Betts, E. D. Carrol, et al; International Meningococcal Genetics Consortium. 2010. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat. Genet. 42: 772-776.
9. Horstmann, R. D., H. J. Sievertsen, J. Knobloch, and V. A. Fischetti. 1988. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc. Natl. Acad. Sci. USA 85: 1657-1661.
10. Fischetti, V. A., R. D. Horstmann, and V. Pancholi. 1995. Location of the complement factor H binding site on streptococcal M6 protein. Infect. Immun. 63: 149-153.
11. Hellwage, J., T. Meri, T. Heikkilä, A. Alitalo, J. Panelius, P. Lahdenne, I. J. Seppälä, and S. Meri. 2001. The complement regulator factor H binds to the surface protein OspE of Borrelia burgdorferi. J. Biol. Chem. 276: 8427-8435.
12. Jarva, H., R. Janulczyk, J. Hellwage, P. F. Zipfel, L. Björck, and S. Meri. 2002. Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8-11 of factor H. J. Immunol. 168: 1886-1894. (Pubitemid 34135790)
13. Iannelli, F., M. R. Oggioni, and G. Pozzi. 2002. Allelic variation in the highly polymorphic locus pspC of Streptococcus pneumoniae. Gene 284: 63-71. (Pubitemid 34219401)
14. Madico, G., J. A. Welsch, L. A. Lewis, A. McNaughton, D. H. Perlman, C. E. Costello, J. Ngampasutadol, U. Vogel, D. M. Granoff, and S. Ram. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177: 501-510. (Pubitemid 43939163)
15. Jarva, H., S. Ram, U. Vogel, A. M. Blom, and S. Meri. 2005. Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J. Immunol. 174: 6299-6307. (Pubitemid 40663822)
16. Schneider, M. C., R. M. Exley, H. Chan, I. Feavers, Y. H. Kang, R. B. Sim, and C. M. Tang. 2006. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol. 176: 7566-7575.
17. Welsch, J. A., S. Ram, O. Koeberling, and D. M. Granoff. 2008. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J. Infect. Dis. 197: 1053-1061.
18. Dunphy, K. Y., P. T. Beernink, B. Brogioni, and D. M. Granoff. 2011. Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood. Infect. Immun. 79: 353-359.
19. Lewis, L. A., J. Ngampasutadol, R. Wallace, J. E. Reid, U. Vogel, and S. Ram. 2010. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 6: e1001027.
20. Granoff, D. M. 2010. Review of meningococcal group B vaccines. Clin. Infect. Dis. 50(Suppl 2): S54-S65.
21. Fletcher, L. D., L. Bernfield, V. Barniak, J. E. Farley, A. Howell, M. Knauf, P. Ooi, R. P. Smith, P. Weise, M. Wetherell, et al. 2004. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 72: 2088-2100.
22. Masignani, V., M. Comanducci, M. M. Giuliani, S. Bambini, J. Adu-Bobie, B. Arico, B. Brunelli, A. Pieri, L. Santini, S. Savino, et al. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197: 789-799.
23. Giuliani, M. M., J. Adu-Bobie, M. Comanducci, B. Aricò, S. Savino, L. Santini, B. Brunelli, S. Bambini, A. Biolchi, B. Capecchi, et al. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. USA 103: 10834-10839.
24. Plested, J. S., J. A. Welsch, and D. M. Granoff. 2009. Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity. Clin. Vaccine Immunol. 16: 785-791.
25. Snape, M. D., T. Dawson, P. Oster, A. Evans, T. M. John, B. Ohene-Kena, J. Findlow, L. M. Yu, R. Borrow, E. Ypma, et al. 2010. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr. Infect. Dis. J. 29: e71-e79.
26. Findlow, J., R. Borrow, M. D. Snape, T. Dawson, A. Holland, T. M. John, A. Evans, K. L. Telford, E. Ypma, D. Toneatto, et al. 2010. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 51: 1127-1137.
27. Granoff, D. M., J. A. Welsch, and S. Ram. 2009. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect. Immun. 77: 764-769.
28. Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-199.
29. Beernink, P. T., and D. M. Granoff. 2008. Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect. Immun. 76: 2568-2575.
30. Beernink, P. T., J. Shaughnessy, S. Ram, and D. M. Granoff. 2010. Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding. Clin. Vaccine Immunol. 17: 1074-1078.
31. Beernink, P. T., C. LoPasso, A. Angiolillo, F. Felici, and D. Granoff. 2009. A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups. Mol. Immunol. 46: 1647-1653.
32. Welsch, J. A., R. Rossi, M. Comanducci, and D. M. Granoff. 2004. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J. Immunol. 172: 5606-5615.
33. Granoff, D. M., S. E. Maslanka, G. M. Carlone, B. D. Plikaytis, G. F. Santos, A. Mokatrin, and H. V. Raff. 1998. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin. Diagn. Lab. Immunol. 5: 479-485.
34. Beernink, P. T., D. A. Caugant, J. A. Welsch, O. Koeberling, and D. M. Granoff. 2009. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A,W-135, and X strains from Africa. J. Infect. Dis. 199: 1360-1368.
35. Frøholm, L. O., D. A. Caugant, E. Holten, E. A. Høiby, E. Rosenqvist, and E. Wedege. 1991. Meningococcal strains isolated from teenage patients during the serogroup B vaccination trial in Norway: serotyping, serosubtyping, immunotyping and clonal analysis. NIPH Ann. 14: 139-143, discussion 144-146.
36. Borrow, R., I. S. Aaberge, G. F. Santos, T. L. Eudey, P. Oster, A. Glennie, J. Findlow, E. A. Høiby, E. Rosenqvist, P. Balmer, and D. Martin. 2005. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol. 12: 970-976.
37. Pajon, R., P. T. Beernink, L. H. Harrison, and D. M. Granoff. 2010. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 28: 2122-2129.
38. Welsch, J. A., and D. Granoff. 2004. Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity. Infect. Immun. 72: 5903-5909.
39. Harris, S. L., W. J. King, W. Ferris, and D. M. Granoff. 2003. Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine. Infect. Immun. 71: 275-286.
40. Pastor, P., F. B. Medley, and T. V. Murphy. 2000. Meningococcal disease in Dallas County, Texas: results of a six-year population-based study. Pediatr. Infect. Dis. J. 19: 324-328.
41. Beernink, P. T., J. A. Welsch, M. Bar-Lev, O. Koeberling, M. Comanducci, and D. M. Granoff. 2008. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein. Infect. Immun. 76: 4232-4240.
42. Cohen, J., and P. Cohen. 1983. Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences. Lawrence Erlbaum Associates, Hillsdale, N.J.
43. Schneider, M. C., B. E. Prosser, J. J. Caesar, E. Kugelberg, S. Li, Q. Zhang, S. Quoraishi, J. E. Lovett, J. E. Deane, R. B. Sim, et al. 2009. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458: 890-893.
44. Giuliani, M. M., L. Santini, B. Brunelli, A. Biolchi, B. Aricò, F. Di Marcello, E. Cartocci, M. Comanducci, V. Masignani, L. Lozzi, et al. 2005. The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect. Immun. 73: 1151-1160.
45. Mascioni, A., B. E. Bentley, R. Camarda, D. A. Dilts, P. Fink, V. Gusarova, S. K. Hoiseth, J. Jacob, S. L. Lin, K. Malakian, et al. 2009. Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086. J. Biol. Chem. 284: 8738-8746.
46. Scarselli, M., F. Cantini, L. Santini, D. Veggi, S. Dragonetti, C. Donati, S. Savino, M. M. Giuliani, M. Comanducci, F. Di Marcello, et al. 2009. Epitope mapping of a bactericidal monoclonal antibody against the factor H binding protein of Neisseria meningitidis. J. Mol. Biol. 386: 97-108.
47. Ngampasutadol, J., S. Ram, S. Gulati, S. Agarwal, C. Li, A. Visintin, B. Monks, G. Madico, and P. A. Rice. 2008. Human factor H interacts selectively with Neisseria gonorrhoeae and results in species-specific complement evasion. J. Immunol. 180: 3426-3435.
48. Lu, L., Z. Ma, T. S. Jokiranta, A. R. Whitney, F. R. DeLeo, and J. R. Zhang. 2008. Species-specific interaction of Streptococcus pneumoniae with human complement factor H. J. Immunol. 181: 7138-7146.
49. Shaughnessy, J., L. A. Lewis, H. Jarva, and S. Ram. 2009. Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin. Infect. Immun. 77: 2094-2103.
50. Murphy, E., L. Andrew, K. L. Lee, D. A. Dilts, L. Nunez, P. S. Fink, K. Ambrose, R. Borrow, J. Findlow, M. K. Taha, et al. 2009. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis. 200: 379-389.